{{Rsnum
|rsid=4905865
|Gene=LOC100507108
|Chromosome=14
|position=99609722
|Orientation=plus
|GMAF=0.3802
|Gene_s=FAM193A
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 61.3 | 36.0 | 2.7
| HCB | 48.9 | 42.3 | 8.8
| JPT | 51.3 | 38.9 | 9.7
| YRI | 4.8 | 34.0 | 61.2
| ASW | 10.5 | 42.1 | 47.4
| CHB | 48.9 | 42.3 | 8.8
| CHD | 38.5 | 49.5 | 11.9
| GIH | 82.2 | 14.9 | 3.0
| LWK | 9.1 | 40.9 | 50.0
| MEX | 27.6 | 48.3 | 24.1
| MKK | 28.2 | 50.6 | 21.2
| TSI | 69.6 | 27.5 | 2.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4905865
|Name_s=
|Gene_s=CCDC85C
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.29, combined P value= 2.57E-04. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470222
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4905865
|overall_frequency_n=79
|overall_frequency_d=126
|overall_frequency=0.626984
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=62
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}